13:55 uur 11-05-2016

Osiris presenteert onderzoek op 26e European Wound Management Association Conference

COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc., het toonaangevende bedrijf in weefselherstel op celniveau dat zich richt op producten voor wondverzorging, orthopedie en sportgeneeskunde, presenteert vergevorderd klinisch onderzoek op de 26e Wound Management Association Conference.

De Conference of the European Wound Management Association (EWMA), de Deutscher Wundkongress en de WundD·A·CH hebben de handen ineengeslagen en bieden deelnemers een breed programma. Het evenement loopt van 11 tot 13 mei in de Duitse stad Bremen. Het overkoepelende thema van de conferentie, met meer dan vijfduizend deelnemers, is ‘Patients – Wounds – Rights’. De conferentie wil met dit thema extra aandacht vestigen op de blijvende noodzaak van een holistische aanpak van wondverzorging. Een van de primaire voorwaarden is de betrokkenheid van interdisciplinaire wondverzorgingsteams. EWMA staat als vertegenwoordiger van veel disciplines, specialiteiten en landen open voor uiteenlopende interessegebieden en perspectieven op wonderverzorging.


Osiris to Present at the 26th European Wound Management Association Conference


COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced clinical and scientific research at the 26 th European Wound Management Association Conference.

The Conference of the European Wound Management Association (EWMA), the 10 th Deutscher Wound Congress (Wundkongress) and the 2 nd Wound D·A·CH (WundD·A·CH) conference have joined forces and are offering participants a comprehensive programme on May 11-13, 2016 in Bremen, Germany. With over 5,000 participants, the overall theme of the conference is “Patients – Wounds – Rights”. With this theme, the conference wishes to highlight the continuous need to ensure that wound management is offered with a holistic approach to the patient. One of the primary preconditions for achieving this is the involvement of interdisciplinary teams in wound management. As an association representing many disciplines, specialties and countries, it lies in the nature of EWMA to open up for widely different interests and perspectives on best practice wound care.

Dr. Daniel Davis, DPM, APMA President, will present at a symposium partnered with Osiris Therapeutics, Inc., and chaired by Dr. Matthew Young, Consultant Diabetologist (Edinburgh) on the Next Generation of Wound Care: Introducing Viable Cryopreserved Placental Membrane. Dr. Alla Danilkovitch, Chief Scientific Officer will summarize the science and clinical evidence for Osiris’ viable placental membrane products. In addition, Dr. Davis will cover the recent Grafix ® complex wound study, the first prospective study on skin substitutes that focuses on patients with wounds that have exposed bone and tendon. He will also review several complex clinical cases that Osiris’ Grafix products have helped close, including a wound that had been present for two years prior to treatment with Grafix.

“Osiris plans to continue growth internationally and we are proud to share our viable allograft knowledge at this International conference,” said Dwayne Montgomery, President and CEO of Osiris. “We look forward to presenting to not only physicians, but also surgeons, nurses, podiatrists, tissue viability specialists and regulators about the exceptional clinical and economic benefits our products offer.”

Scientific and Clinical Posters

  • Antimicrobial Peptides in Human Cryopreserved Viable Amniotic Membrane Inhibit Bacterial Growth
  • Understanding Placental Products: Impact of Commercial Preservation Methods on Anti-Inflammatory and Angiogenic Properties
  • Unique Feature of Living Amniotic Tissue: Cell Protection from Oxidant-Induced Damage via the Release of Anti-oxidant Mediators
  • A Comparison Study between Viable and Devitalized Cryopreserved Human Amniotic Membrane
  • Characterization of Novel Human Mesenchymal Stem Cell-Containing Skin Substitute for the Treatment of Wounds
  • Treatment of Challenging Lower Extremity Wounds with Bone and Tendon Exposure: Using a Uniquely Viable and Intact Cryopreserved Human Placental Membrane Graft for Closure
  • Wound Closure of Chronic Foot Ulcers using Cryopreserved Human Amniotic Membrane (cHAM)
  • The Use of an Intact Viable Cryopreserved Placental Membrane (vCPM) in the Closure of Chronic Wounds
  • Challenging Lower Limb Ulcerations in Patients with Impaired Tissue Perfusion: Application of a Viable Intact Cryopreserved Human Amniotic Membrane to Achieve Wound Closure
  • Expedient Wound Closure Utilizing Viable Placental Tissue in Serious Limb Threatening Infection: A Case Study

About Osiris Therapeutics

Osiris Therapeutics, Inc., based in Columbia, Maryland, is a leader in researching, developing and marketing cellular regenerative medicine products that improve the health and lives of patients and lower overall healthcare costs. Having developed the world’s first approved stem cell drug, Osiris works to further advance the medical field. Osiris’ research and development in biotechnology focuses on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO , a viable bone matrix, Cartiform ®, a viable osteochondral allograft, Grafix, a cryopreserved placental membrane, TruSkin , a viable human skin allograft and Stravix , a durable placental allograft.

Osiris, Grafix and Cartiform are registered trademarks of Osiris Therapeutics, Inc.; TruSkin and Stravix are trademarks of Osiris Therapeutics, Inc. BIO 4 is a registered trademark of Stryker Corporation (NYSE: SYK). More information can be found on the company’s website, www.Osiris.com. (OSIR-G)

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our biologic drug candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy biologic drug candidates and marketed Biosurgery products (including Grafix, BIO4, Cartiform, TruSkin and Stravix); our cash needs; patents, trademarks and other proprietary rights; the safety and ability of our products and potential products to treat disease; our ability to supply a sufficient amount of our marketed products or product candidates and, if approved or otherwise commercially available, products to meet demand; our costs to comply with governmental regulations; our plans for sales and marketing; our plans regarding facilities; types of regulatory frameworks we expect will be applicable to our products and potential products; results of our scientific research; the timing of our amended 2015 filings; and the engagement of our successor accounting firm. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled “Risk Factors” in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the United States Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.


For additional information, please contact:
Osiris Therapeutics, Inc.
Amanda Badillo, 443-545-1834
For International inquiries, please contact:
Osiris Therapeutics, Inc.
Paul Saunders, +44 771 388 5257

Check out our twitter: @NewsNovumpr